We had an opportunity to catch up with EAN Programme Committee Chair Tony Marson (Liverpool, UK), who talked to us on the topic of the special session he moderated entitled: How to use ‘big data’ and digital technology to improve epilepsy care and patient outcomes.
1. What have we learned from audits about the costs of inadequately coordinated care in epilepsy? (0:04)
2. How can the use of ‘big data’ help neurologists in making point-of-care decisions? (1:54)
3. What are the most useful components of a ‘pathways of care’ approach in epilepsy services? (3:00)
4. What are the major barriers in implementing such approaches? (4:12)
5. Could you tell us a little about the European Brain Council (EBC) Value of Treatment of Epilepsy project? (4:36)
Speaker disclosure: UCB Pharma funded the UK audit discussed in this video interview.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
Share this Video
Related Videos In Epilepsy
Pat Penovich, AES 2020 – The Patient Experience With Diazepam Nasal Spray
It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit […]
Martin Brodie, CONy 2020 – Combination Antiepileptic Drug Therapy
It was a pleasure to speak with Martin Brodie (President, International Bureau for Epilepsy and co-Section Head of Epilepsy for CONy), who spoke with us on the topic of the debate session he participated in: Should combination antiepileptic drug (AED) therapy be offered immediately after failure of a single antiepileptic drug? Questions Could you tell […]
Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!